NasdaqGM - Delayed Quote USD
Cognition Therapeutics, Inc. (CGTX)
At close: November 6 at 4:00 PM EST
After hours: 7:30 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
32,037.0000
25,919.0000
21,334.0000
11,151.0000
6,552.0000
Operating Income
-32,037.0000
-25,919.0000
-21,334.0000
-11,151.0000
-6,552.0000
Net Non Operating Interest Income Expense
-28.0000
-27.0000
-28.0000
-893.0000
-1,751.0000
Other Income Expense
983.0000
158.0000
-35.0000
328.0000
464.0000
Pretax Income
-31,082.0000
-25,788.0000
-21,397.0000
-11,716.0000
-7,839.0000
Net Income Common Stockholders
-31,082.0000
-25,788.0000
-21,397.0000
-16,248.0000
-12,073.0000
Diluted NI Available to Com Stockholders
-31,082.0000
-25,788.0000
-21,397.0000
-16,248.0000
-12,073.0000
Basic EPS
-0.93
-0.86
-0.91
-3.13
-0.56
Diluted EPS
-0.93
-0.86
-0.91
-3.13
-0.56
Basic Average Shares
33,800.5710
30,029.0870
23,640.1990
5,190.8830
21,371.4120
Diluted Average Shares
33,800.5710
30,029.0870
23,640.1990
5,190.8830
21,371.4120
Total Operating Income as Reported
-58,714.0000
-50,724.0000
-43,551.0000
-28,598.0000
-17,407.0000
Total Expenses
32,037.0000
25,919.0000
21,334.0000
11,151.0000
6,552.0000
Net Income from Continuing & Discontinued Operation
-31,082.0000
-25,788.0000
-21,397.0000
-11,716.0000
-7,839.0000
Normalized Income
-30,887.0000
-25,788.0000
-21,397.0000
-14,368.0000
-7,909.0000
Interest Expense
28.0000
27.0000
28.0000
893.0000
1,751.0000
Net Interest Income
-28.0000
-27.0000
-28.0000
-893.0000
-1,751.0000
EBIT
-31,054.0000
-25,761.0000
-21,369.0000
-10,823.0000
-6,088.0000
EBITDA
-30,798.0000
-25,509.0000
-21,134.0000
-10,730.0000
-5,990.0000
Reconciled Depreciation
256.0000
252.0000
235.0000
93.0000
98.0000
Net Income from Continuing Operation Net Minority Interest
-31,082.0000
-25,788.0000
-21,397.0000
-11,716.0000
-7,839.0000
Total Unusual Items Excluding Goodwill
-195.0000
--
--
2,652.0000
70.0000
Total Unusual Items
-195.0000
--
--
2,652.0000
70.0000
Normalized EBITDA
-30,603.0000
-25,509.0000
-21,134.0000
-13,382.0000
-6,060.0000
12/31/2020 - 10/8/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INAB IN8bio, Inc.
0.3337
-9.57%
ACTU Actuate Therapeutics, Inc. Common stock
8.70
-1.14%
ALRN Aileron Therapeutics, Inc.
3.8400
-2.29%
SILO Silo Pharma, Inc.
1.1800
+6.31%
AZTR Azitra, Inc.
0.4941
+2.77%
SPRC SciSparc Ltd.
0.2395
+4.27%
ELEV Elevation Oncology, Inc.
0.5500
-1.79%
LYEL Lyell Immunopharma, Inc.
1.4800
+19.35%
CYTO Altamira Therapeutics Ltd.
0.5049
-2.72%
ALZN Alzamend Neuro, Inc.
1.4500
-11.59%